Acadia Pharmaceuticals Inc (NASDAQ: ACAD)

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into meaningful innovation for underserved neurological and rare disease communities worldwide. The company has two core franchises neuroscience and neuro rare diseases. Its neuroscience franchise is anchored by the commercial product NUPLAZID pimavanserin which is the first and only drug approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Its neuro rare disease franchise is anchored by the commercial product DAYBUE trofinetide which is the first and only drug approved for the treatment of Rett syndrome. The company also maintains a pipeline of earlier stage product candidates aimed at addressing additional unmet needs in CNS disorders and rare diseases.

Revenue is derived almost exclusively from net product sales of NUPLAZID and DAYBUE. NUPLAZID received FDA approval in April 2016 for hallucinations and delusions associated with Parkinson’s disease psychosis and was launched in the United States in May 2016. DAYBUE received FDA approval in March 2023 for Rett syndrome and was launched in the United States in April 2023. For the nine months ended September 30 2025 net product sales of NUPLAZID were $505.7 million and net product sales of DAYBUE were $281.8 million for a total of $787.5 million compared with $698.2 million for the same period in 2024. The increase reflects higher unit sales and a higher average net selling price for both products.

The company operates through the following segments: Neuroscience and Neuro rare diseases.

• Neuroscience: This segment focuses on the development and commercialization of NUPLAZID pimavanserin the first and only FDA approved drug for hallucinations and delusions associated with Parkinson’s disease psychosis and also includes the advancement of pipeline candidates such as ACP-204 for Alzheimer’s disease psychosis and Lewy Body Dementia with psychosis ACP-711 for essential tremor and ACP-211 for major depressive disorder.

• Neuro rare diseases: This segment focuses on the development and commercialization of DAYBUE trofinetide the first and only FDA approved drug for the treatment of Rett syndrome and includes earlier stage programs such as ACP-101 which was investigated for hyperphagia in Prader Willi syndrome but development was discontinued after Phase 3 results.

NUPLAZID holds a pioneering position as the first and only FDA approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis. DAYBUE holds a pioneering position as the first and only FDA approved treatment for Rett syndrome. These first in class designations give the company a competitive advantage in markets where no other approved therapies exist. The company’s focus on rare and neglected neurological indications allows it to build strong brand recognition and to leverage its expertise in neuroscience drug development.

The company serves patients diagnosed with Parkinson’s disease psychosis and Rett syndrome as well as healthcare providers such as neurologists psychiatrists and specialty pharmacies that prescribe and dispense its products. Distribution occurs through specialty pharmacy networks and institutional channels in the United States and in select international markets where DAYBUE has received regulatory approval.